血清素能致幻剂对大脑影响的多模态神经影像研究
本文综述了裸盖菇素、麦角酸二乙酰胺和N,N-二甲基色胺等致幻剂在人体内给药后脑功能改变的功能磁共振成像(fMRI)与PET研究现状,旨在阐明其神经生物学治疗反应机制,并推动神经精神疾病的诊断与治疗。
要点
- 致幻剂被认为可诱导神经可塑性效应并改变脑功能网络,但治疗反应的神经生物学机制仍不明确。
- 定量神经影像可用于揭示此类新兴疗法的神经生物学机制并量化患者治疗反应。
- 本综述聚焦裸盖菇素、麦角酸二乙酰胺和N,N-二甲基色胺给药后人体脑功能改变的fMRI与PET证据。
核心结论
- 致幻剂可能通过诱导神经可塑性效应和改变脑功能网络发挥治疗作用,但支持神经生物学治疗反应的机制仍不明确。
- 定量神经影像可为了解此类新兴疗法的神经生物学机制和量化患者治疗反应提供独特视角。
研究设计与样本
- 本文为综述,汇总裸盖菇素、麦角酸二乙酰胺或N,N-二甲基色胺给药后人体参与者脑功能改变的fMRI与PET研究现状;原文未报告检索范围、纳入文献数量、样本量或中心数。
临床应用与阅片要点
- 作者希望传播致幻剂与神经影像相关的认识,以改善神经精神疾病的诊断与治疗。
局限性
- 原文未报告局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
英文原文(摘要)· 点击展开
The neurobiological mechanisms underpinning psychiatric disorders such as treatment-resistant major depression, post-traumatic stress disorder, and substance use disorders, remain unknown. Psychedelic compounds, such as psilocybin, lysergic acid diethylamide, and N,N-dimethyltryptamine, have emerged as potential therapies for these disorders because of their hypothesized ability to induce neuroplastic effects and alter functional networks in the brain. Yet, the mechanisms underpinning the neurobiological treatment response remain obscure. Quantitative neuroimaging is uniquely positioned to provide insight into the neurobiological mechanisms of these emerging therapies and quantify the patient treatment response. This review aims to synthesize our current state-of-the-art understanding of the functional changes occurring in the brain following psilocybin, lysergic acid diethylamide, or N,N-dimethyltryptamine administration in human participants with fMRI and PET. We further aim to disseminate our understanding of psychedelic compounds as they relate to neuroimaging with the goal of improved diagnostics and treatment of neuropsychiatric illness.
引用
- Frautschi PC, Singh AP, Stowe NA, et al. Multimodal Neuroimaging of the Effect of Serotonergic Psychedelics on the Brain. AJNR Am J Neuroradiol. 2024. PMID: 38360790. doi:10.3174/ajnr.A8118
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。